Abstract
Efforts to develop orally available gonadotropin-releasing hormone (GnRH) receptor antagonists have led to the discovery of several classes of potent nonpeptide antagonists. Here we investigated molecular interactions of three classes of nonpeptide antagonists with human, rat, and macaque GnRH receptors. Although all are high affinity ligands of the human receptor (K(i) <5 nm), these compounds show reduced affinity for the macaque receptor and bind only weakly (K(i) >1 microm) to the rat receptor. To identify residues responsible for this selectivity, a series of chimeric receptors and mutant receptors was constructed and evaluated for nonpeptide binding. Surprisingly, 4 key residues located in the amino terminus (Met-24) and extracellular loops II (Ser-203, Gln-208) and III (Leu-300) of the GnRH receptor appear to be primarily responsible for species-selective binding. Comparisons of reciprocal mutations suggest that these may not be direct contacts but rather may be involved in organizing extracellular portions of the receptor. These data are novel because most previous reports of residues involved in binding of nonpeptide ligands to peptide-activated G protein-coupled receptors, including the GnRH receptor as well as mono-amine receptors, have identified binding sites in the transmembrane regions.
Highlights
Gonadotropin-releasing hormone (GnRH)1 is a linear decapeptide amide, pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-GlyNH2, that regulates the reproductive endocrine axis in both male and female vertebrates [1, 2]
4 key residues located in the amino terminus (Met-24) and extracellular loops II (Ser203, Gln-208) and III (Leu-300) of the gonadotropin-releasing hormone (GnRH) receptor appear to be primarily responsible for species-selective binding
If one compares the nearly 5-fold improvement in binding of compound III achieved by the rGnRHR(T24M) mutant relative to the native rat receptor with the nearly 2000-fold loss in affinity caused by the reciprocal hGnRHR(M24T) mutation in the human receptor, it appears likely that Met-24 is involved in organizing an extracellular region of the receptor for high affinity nonpeptide binding, rather than contributing a direct interaction with the ligand
Summary
GnRH, gonadotropin-releasing hormone; hGnRHR-R, human GnRHR; GnRHR, gonadotropin-releasing hormone receptor; rGnRH-R, rat GnRHR; TM, transmembrane domain; CHO, Chinse hamster ovary; ECL, extracellular loop. Peptide drugs that inhibit the action of GnRH have proven useful in regulating the hypothalamic-pituitary-gonadal axis and are routinely used for ablation of gonadal steroids. The requirement for daily injection or implantation of long acting depots has prompted a number of groups to attempt to develop orally active, nonpeptide antagonists (for a review, see Ref. 7) These efforts have been hindered in part by the species selectivity that is observed for most nonpeptide GnRH antagonists. We report that species selectivity for three families of nonpeptide GnRH antagonists is determined by residues in the amino terminus and extracellular loops II and III.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.